Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer

  • Technology appraisal guidance
  • TA737
  • Published: 
  • Last updated: 

Evidence

Supporting evidence